Back to search

Article

CCT-217: A Landmark Gene Silencing Therapeutic for Weight Loss That Enhances Lean Mass Composition, Reduces Visceral, Subcutaneous Fat and Restores Metabolic Health in Obesity through Browning

2024-12-30

Abstract excerpt

According to the CDC, between 2017 and March 2020, 41.9% of U.S. adults aged 20 and older had obesity, with 9.2% experiencing severe obesity, affecting over 100 million and 22 million adults, respectively. Obesity prevalence increased from 30.5% in 1999-2000 to 41.9% in 2017-2020, while severe obesity rose from 4.7% to 9.2%. As per CDC projection, by 2030, nearly half of the US adults will be obese, with a quarter...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2cbdc994-e3dc-56a9-87a5-21f2e5f53486
DOI
10.1101/2024.12.30.630715
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CCT-217: A Landmark Gene Silencing Therapeutic for Weight Loss That Enhances Lean Mass Composition, Reduces Visceral, Subcutaneous Fat and Restores Metabolic Health in Obesity through BrowningDOI 10.1101/2024.12.30.630715
Select a neighboring publication to make it the new centre.